Sugarbaker: Mesothelioma Clinical Trial May Be ‘Home Run’
Thoracic surgeon and mesothelioma visionary Dr. David Sugarbaker already is thinking two steps ahead, anticipating the optimal utilization of this latest clinical trial drug combination. That’s what leaders do. A phase II, multicenter clinical trial involving the antibody-drug conjugate anetumab ravtansine (BAY 94-9343) for patients with stage IV pleural mesothelioma opened recently with considerable expectations,…
The post Sugarbaker: Mesothelioma Clinical Trial May Be ‘Home Run’ appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.